In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Glycation of proteins in the peritoneum might occur due to the extremely high glucose concentrations (75 to 214 mmol/liter) in the dialysate of patients on continuous ambulatory peritoneal dialysis (CAPD) and may be involved in the etiology of ultrafiltration failure. Formation of both early (glycated albumin) and late (advanced glycation end products; AGE, measured as protein-derived fluorescence intensity, Fl) Maillard reaction products was studied in vitro in dialysis fluids obtained from seven patients on CAPD and in phosphate buffered saline (PBS) controls paired for glucose and albumin concentrations. Percentage glycated albumin (median, range) increased (P < 0.02) from baseline after 10 and 21 days in both dialysate and PBS but did not differ (P> 0.05) between the two media at any time point (day 0, 3.6, 3.1-4.5 vs. 4.1, 3.0-4.6; day 10, 19.4, 7.9-54.8 vs. 19.1, 8.7-50.1; day 21, 29.0, 12.0-75.6 vs. 30.0, 11.7-69.8). Glycated albumin formation was linearly related to the glucose concentration (r> 0.98, P < 0.001) in both dialysate and PBS at 10 and 21 days.
In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Glycation of proteins in the peritoneum might occur due to the extremely high glucose concentrations (75 to 214 mmol/liter) in the dialysate of patients on continuous ambulatory peritoneal dialysis (CAPD) and may be involved in the etiology of ultrafiltration failure. Formation of both early (glycated albumin) and late (advanced glycation end products; AGE, measured as protein-derived fluorescence intensity, Fl) Maillard reaction products was studied in vitro in dialysis fluids obtained from seven patients on CAPD and in phosphate buffered saline (PBS) controls paired for glucose and albumin concentrations. Percentage glycated albumin (median, range) increased (P < 0.02) from baseline after 10 and 21 days in both dialysate and PBS but did not differ (P> 0.05) between the two media at any time point (day 0, 3.6, 3.1-4. Glycated albumin formation was linearly related to the glucose concentration (r> 0.98, P < 0.001) in both dialysate and PBS at 10 and 21 days.
FT (U/g/liter albumin, median, range) increased (P < 0.02) from baseline after 10 and 21 days in dialysate but only after 21 days in PBS; this increase was significantly greater (P < 0.02) in dialysate than in PBS after 10 and 21 days (day 0, 41, 36-46 vs. 42, 37-46; day 10, 99, 88-161 vs. 51, 34-68; day 21, 113, 102-239 vs. 68, 54-91). After 21 days, FT was significantly related to glucose concentration (r = 0.90, P < 0.01) and to % glycated albumin (r = 0.92, P < 0.01) in PBS but not in dialysate (P > 0.05). AGE formation, but not glycation, decreased as a function of the dialysate dwell time and was inhibited by aminoguanidine. Our results demonstrate that formation of AGE products occurs in dialysis fluid and that factors in dialysate can modulate this process.
Soluble and structural proteins may undergo condensation reactions with sugars, predominantly through E-amino groups on lysine and hydroxylysine residues. These reactions occur in the absence of enzyme catalysis at a rate related to the protein [1] and sugar concentrations and the time of exposure of the protein to that sugar [21. In vivo, glucose is quantitatively the most important sugar involved in these reactions [3] . The reaction is known as the Maillard reaction. Initially a ketoamine known as the Amadori product (glycated protein) is formed. This can undergo a further series of dehydration and rearrangement reactions to form products known as advanced glycation end (AGE) products. These are highly insoluble, fluorescent, pigmented polymers which form inter-molecular cross links [2] , even after the initial glucose accumulate over the lifetime of the protein [51. Although the formation of protein-derived fluorescence may be the result of glucose-mediated oxidation reactions [6, 7] as well as Maillard reactions, it is probable that the induction of fluorescence represents glucose-mediated protein damage. In the present study the formation of protein-derived fluorescence has been used as a marker of AGE product formation.
In the clinical setting most interest in these reactions stems from the demonstration that high levels of early [8] and late [9, 10] Maillard reaction products can be demonstrated in the blood and tissues of patients with diabetes mellitus as a consequence of hyperglycemia. Protein glycation may play an important role in the development of the long-term complications of diabetes mellitus [5, 11] . However, these reactions may also occur in other situations where high glucose concentrations prevail. In particular, glycation of soluble and structural proteins in the peritoneum might occur as a result of the extremely high glucose concentrations (75 to 214 mmol/liter) present in the dialysate of patients on continuous ambulatory peritoneal dialysis (CAPD) and may well have deleterious consequences [12] . Glycation of peritoneal membrane proteins may be involved in the etiology of ultrafiltration failure in CAPD. Similarities can be drawn between the pathological changes seen irs diabetes mellitus and those in the peritoneal membrane from patients on CAPD. Basement membrane thickening, which is the classical hallmark of diabetic vascular disease [13, 14] and may be caused by glycation and AGE product formation on structural proteins [15] , has also been observed in the basal lamina of the peritoneal capillaries [16, 171 and the mesothelium [17, 18] in peritoneal biopsies of CAPD patients. Basement membrane duplication in non-diabetic uraemic patients occurs after fairly short periods (2 to 66 months) of CAPD and multiple replication exceeding five layers may be seen in some subjects after longer periods [17] . In uremic diabetics, thickening of the peritoneal capillary basement membrane but not of the mesothelium is present before commencement of dialysis, but increases with increasing time on CAPD, and capillary occlusion occurs in some patients [17] .
In diabetes, basement membrane thickening may be associated with increased capillary permeability to solutes [19] . The influence of peritoneal basement membrane thickening on the transport of water and solutes during CAPD is not known, but increased permeability to glucose is associated with decreased ultrafiltration due to a lower glucose gradient [20] .
We have previously shown [21] that endogenous glycated albumin levels in peritoneal dialysis fluid from patients on CAPD are higher than those in concurrent serum samples, due to either intraperitoneal glycation or preferential transport across the peritoneal membrane. In vitro experiments confirmed that glycation occurred in peritoneal dialysis fluid and at a rate related to glucose concentration [21] . In CAPD patients the peritoneal membrane is continually exposed to high glucose concentrations and pathological effects are more likely to relate to the formation of late, as opposed to early, Maillard reaction products. In the present study, in vitro experiments have been designed to study the formation of early (glycated, Amadori product) and late (AGE product) Maillard reaction products in peritoneal dialysis fluid.
Methods

Reagents
Glyco-Gel test kits, containing columns consisting of a 1 ml bed volume of Glycogel B (immobilized m-aminophenyl boronic acid), were obtained from Pierce and Warriner (Chester, UK). Chemicals were Analar grade from BDH/Merck Ltd. (Poole, Dorset, UK), unless specified otherwise. Buffers (equilibration wash buffer, EWB; elution buffer for the non-glycated fraction, EB-NG; elution buffer for the glycated fraction, EB-G) were as described previously [22] . All buffers and columns were stored in the dark at 4°C and were equilibrated to room temperature before use. One ml of dialysate or PBS (containing approximately 1 mg HSA) was ultrafiltered (Centricon-30, 2200 g, 16°C, 45 mm) to remove low Mr compounds. Retained fluid and protein (approximately 20 to 40 'id) was washed twice by repeated ultrafiltration with two aliquots (2 ml each) of PBS, before recovering the protein by inverting the microconcentrator and re-centrifuging (1500 g, room temperature, 5 mm) with two aliquots (150 rl each) of PBS. Ultrafiltrates were retained and assayed for albumin to ensure that no albumin loss had occurred. The retentate volume was diluted to 2 ml with PBS.
Dialysate glycated albumin was determined by affinity chromatography as described previously [21] . Fluorescence was determined at the excitation and emission maxima (Aexcjtatjon 350 nm, Aemjssio,, 430 nm, slit widths 10 nm) in duplicate in glass cuvettes against a PBS blank. Albumin concentration in the samples was determined by radioimmunoassay [24] . Fluorescence intensity (Fl) was expressed as arbitrary units/glliter albumin. Two-and fivefold dilution in PBS of a sample containing 0,48 glliter albumin and having a FT of 154, had FT's (corrected for dilution and blank) of 142 and 150, respectively, demonstrating that the protein-derived fluorescence gave a linear response. The fluorescence spectra of albumin which had been incubated for 21 days in glucose-containing dialysate or PBS were similar. The fluorescence spectrum of the glass cuvettes alone did not change over the spectrum studied.
In vitro formation of early and late Maillard reaction products Effect of peritoneal dialysis fluid on rate of formation. Uremic ultrafiltrates (50 ml, N = 7, glucose 15 to 93 mmol/liter) were prepared from dialysates drained from CAPD patients at the end of a routine dwell time by ultrafiltering (Centriprep 30) to remove endogenous albumin and molecules of Mr >30,000 but not low Mr solutes such as glucose. The albumin concentration was measured to confirm total removal of endogenous albumin.
Ultrafiltrates were buffered to pH 7.4 by the addition of sodium phosphate buffer to a final concentration of 50 mmol/liter. Bacterial growth was inhibited by the addition of NaN3 (0.1%). A fresh (unused) dialysis fluid (76 mmol/liter glucose) was treated identically. For each dialysate sample, paired PBS controls were treated as above and spiked to give glucose concentrations equivalent to those of each dialysate. All samples were then spiked with HSA to an approximate concentration of 1 glliter. PBS with albumin but not glucose added was used as a control.
Solutions were divided into 5 ml aliquots in glass tubes and incubated at 37°C. Aliquots were removed at 0, 10 and 21 days and stored at -70°C until analysis. Repeat measurement of glucose at the end of the experiment ensured that no loss had occurred.
Samples were then thawed, mixed well and glycated albumin and FT determined. Fl's determined in four uremic ultrafiltrates incubated for 21 days in the absence of albumin were low (mean 1,3 units) and did not increase significantly from baseline (mean 2.2 units), confirming that the F! of ultrafiltered dialysis fluid itself did not change in the absence of albumin.
Effect of dwell time on rate of formation of Maillard products. Uremic ultrafiltrates were prepared from dialysates (initial glucose concentration 126 mmol/liter) removed 0, 2 and 4 hours after instillation into the peritoneal cavity in patients undergoing peritoneal equilibration tests as part of their routine clinical assessment. To obtain sufficient material, two pools were prepared, each containing dialysate from five patients. To eliminate the effect of differing glucose concentrations, the two and four hour pools were spiked with glucose to give concentrations equivalent to those of the 0 hour pool (110 mmol/liter). NaN3 (0.1%) was added and fluids were buffered as before and spiked with HSA (1 g/liter). Glycated albumin and F! were determined on 5 ml aliquots which had been either frozen immediately (-70°C) or incubated at 37°C for nine days.
Aminoguanidine inhibition. Dialysate from a single patient at the end of a four hour dwell was used to prepare a uremic ultrafiltrate (60 ml, glucose concentration 65 mmol/liter) which was buffered and NaN3 (0.1%) added as above followed by NSA (approximately 1 g/liter). Aliquots (10 ml) of this solution (and an equivalent PBS control) were then placed in glass tubes and spiked to give aminoguanidine concentrations of 0, 25, 50, 100, 200 and 500 mmol/liter. with a glucose concentration of 78 mmol/liter was fresh (unused) and was not included in the statistical analysis. Results were analyzed using parametric or non-parametric statistics as appropriate. Parametric data were analyzed using the paired t-test (paired-t) and the Pearson product moment correlation coefficient (r) and standard regression. Non-parametric data were analyzed using the Wilcoxon's matched-pairs signed-ranks test (Wilcoxon's). Data were analyzed either manually or using 
Results
The percentage of glycated albumin increased significantly from baseline (day 0) after 10 and 21 days in both dialysate and PBS (P < 0.02 Wilcoxon's test; Fig. 1 and Table 1 ). There was no Glucose, mmol/Iiter significant difference (P> 0.05 Wilcoxon) between the % glycated albumin in the dialysate and PBS controls at 0, 10 or 21 days (Table 1 ). The formation of glycated albumin was linearly related to the glucose concentration (mmol/liter) (dialysate % glycated albumin10 day. = -3.27 + 0.60 glucose, r = 0.99, P < 0.001; dialysate % glycated albumin21 days = -0.13 + 0.83 glucose, r = 0.99, P < 0.001; PBS % glycated albumin10 days = -0.37 + 0.55 glucose, r = 0.98, P < 0.001; PBS % glycated albumin21 days = 4.13 + 0.75 glucose, r = 0.99, P < 0.001; Fig. 2 ). The rate of glycated albumin formation in a fresh (unused) dialysis fluid was similar to that in dialysates of equivalent glucose concentration (Fig. 2) .
Fl (U/glliter albumin) increased from baseline after 10 and 21 days in dialysate but only after 21 days in PBS (P < 0.02 Wilcoxon; Fig. 3 and Table 1 ). This increase was significantly greater in dialysate than in PBS after 10 and 21 days (P < 0.02 Wilcoxon; HSA incubated in PBS in the absence of glucose contained 3.5%, 2.6% and 1.6% glycated albumin and had a FT of 45.6, 48.6 and 51.3 U/glliter albumin at 0, 10 and 21 days, respectively.
In dialysates taken from patients 0, 2 and 4 hours after commencing dialysis, formation of protein-derived fluorescence decreased with increasing dwell time of dialysate, while increases in glycated albumin were similar irrespective of dwell time (Fig.   6 ).
The development of protein-derived fluorescence, but not protein glycation, was inhibited by aminoguanidine at a concentration of 25 mmollliter. At higher concentrations of aminoguanidine (>100 mmol/liter), there was a decrease in the amount of glycated albumin formed (Table 2) . Discussion Albumin has been used as a model protein to study the early and late Maillard reaction in vitro in peritoneal dialysis fluid.
Formation of the early glycated Amadori product in both dialysate and PBS was linearly related to glucose concentration, as has been demonstrated in other in vitro buffered systems [21, 25, 26] .
After three weeks of incubation, glycation rates did not differ between dialysates and their paired PBS controls, suggesting that dialysis fluid does not contain inhibitors or promoters of the early Maillard reaction other than glucose.
The development of diabetic complications is more likely to be related to the formation of late, as opposed to early, products of the Maillard reaction [5] , and these products may be more relevant to the development of peritoneal pathology. It has been demonstrated here that protein-derived fluorescence, and hence probably AGE products, readily forms in vitro in peritoneal dialysis fluid.
In PBS controls, formation of protein-derived fluorescence was related to glucose concentration and to the % glycated albumin. Similarly, Eble, Thorpe and Baynes [4] have shown glucosedependent cross linking of ribonuclease A in vitro to be markedly dependent on glucose concentration. In dialysate, however, despite the strong association between glucose concentration and early Maillard product formation, formation of AGE products was not related to either glucose concentration or % glycated albumin. This suggests that other factors may be important in AGE product formation in dialysis fluid. This is supported by the fact that AGE products were formed to a lesser extent in PBS than in dialysate samples paired for glucose concentration.
Additionally, AGE product formation was greater in either fresh dialysis fluid or in dialysate which had been removed from patients immediately after instillation, than in dialysates which had remained for longer periods in the peritoneal cavity. This effect cannot be related to pH or glucose concentration since these factors were controlled. The results suggest either that dialysis fluid contains a factor (or factors) which promotes AGE product formation, and that its concentration diminishes during dialysis, or that the concentration of an inhibitor of the reaction increases in the dialysate during dialysis. Clearly, as dialysis progresses so the concentration in dialysate of dialyzable uremic toxins increases. A spectrum of low Mr guanidino-type compounds, including creatinine, guanidine, methylguanidine and guanidinosuccinic acid, accumulate in the serum of patients with chronic renal failure [27] and are readily cleared across the peritoneal membrane during peritoneal dialysis [28, 291 . Given the structural similarity of these compounds to aminoguanidine, a known inhibitor of the Maillard reaction (vide infra), it has been suggested that they may inhibit AGE product formation in proteins by a similar mechanism [30] . However, none of the guanidino compounds contain the reactive hydrazine group found in aminoguanidine and reductive amination of the primary amino group would require harsh conditions unlikely to occur in vivo [31] . Indeed, it has recently been shown that methylguanidine is only 7% as effective as aminoguanidine itt inhibiting AGE product formation [32] . Although guanidine has been demonstrated to cause massive reductions in fluorescence generation in BSA in vitro [33] , the concentrations used were 100,000-fold in excess of those likely to be encountered in dialysate [28] .
Urea (200 mmol/liter), a non-guanidino nitrogenous compound, also reduced fluorescence formation in BSA in vitro [33] .
This could be either as a consequence of protein denaturation decreasing its susceptibility to oxidative damage [33] or due to carbamylation of protein amino or sulphydryl groups [34] [35] [36] interfering with fluorescence generation in protein. Fresh dialysis fluid may contain 3-deoxyglucosone, a potential reactant in the late stages of the Maillard reaction [6, 38] . Under hot acid conditions, glucose undergoes dehydration to form 5-hydroxymethylfurfural [39] . Sterilization of peritoneal dialysis fluid mimics these conditions [40, 41] and this product has been found as a spontaneous breakdown product of glucose in dialysate [42]. 3-Deoxyglucosone has been postulated as an intermediate in the formation of 5-hydroxymethylfurfural from glucose [43] .
These findings may be of particular relevance to ultrafiltration failure. Although estimates of the importance of ultrafiltration failure as a cause of morbidity in CAPD patients varies greatly between studies, after peritonitis it is the single major cause of failure of CAPD [44, 451 and subclinical loss of ultrafiltration is likely to be even more common [46] . Diminishing ultrafiltration is often treated by increased use of more hypertonic solutions [47] and/or decreased dwell times [48] . This will increase exposure of the peritoneum to glucose and the time during which conditions favoring AGE product formation pertain, that is, increase the amount of time during which potential promoters of the reaction are abundant and/or decrease the time during which inhibitors of the reaction are present. Hence, if AGE product formation is important, therapeutic interventions currently used in ultrafiltration failure may be self-limiting.
Should the Maillard reaction prove to be relevant to the etiology of ultrafiltration failure, it may be possible to include inhibitors of the reaction in the dialysis fluid. In an in vitro model it has been shown that low concentrations of aminoguanidine (25 mmol/liter) inhibit AGE formation with no appreciable effect on glycated albumin formation, while high concentrations (>100 mmol/liter) affected both early and late Maillard reactions.
The mechanism of action of aminoguanidine is uncertain: Khatami et al [49] observed apparent inhibition of Amadori product formation at relatively low concentrations of aminoguanidine (5 to 50 mmol/Iiter), and suggested that the major action of aminoguanidine is to inhibit the formation of Amadori product by competing with protein for free open-chain glucose. Although this could explain the observed decrease in glycated albumin formed at high concentrations of aminoguanidine in the present study, it is not consistent with the results at low concentrations. It seems likely that the major effect of aminoguanidine in the study of Khatami et al [49] was to inhibit the reaction of protein with a fast-reacting contaminant of their radioactive glucose preparation This present study is consistent with a post-Amadori effect. Aminoguanidine contains a nucleophilic hydrazine group which will attack the electron-deficient carbonyl carbon. Both triazine and dihydrazone products have been isolated following the reaction of one or two aminoguanidine molecules, respectively, with an Amadori product [511. Brownlee et al [52] suggested that by blocking the reactive carbonyl groups on the ketoamine, aminoguanidine prevented cross-link formation. Additionally, dicarbonyl compounds such as 3-deoxyglucosone, which have been implicated in the formation of AGE products [6, 38] , have two such carbonyl groups and aminoguanidine may trap these intermediate compounds [531. Alternatively, it may inhibit fluorescence generation derived from lipid peroxidation products [33] , The present study cannot distinguish between these potential mechanisms.
We have demonstrated for the first time that formation of AGE products occurs in dialysis fluid and that factors in dialysate may modulate this process. Although the number of patients studied is small, the difference between patient samples and control solutions is unequivocal. The possibility that fresh dialysis fluid may contain promotors of this reaction needs investigation given its potential pathological consequences. Similarly, the possibility that potent naturally occurring inhibitors of the advanced glycation reaction may occur in vivo is important, both from a physiological and a pharmacological viewpoint. Our observations have been made in in vitro studies but, by analogy with diabetes mellitus, it is likely that they are of clinical relevance.
It is unlikely that glycation and subsequent AGE product formation on peritoneal structural proteins would be the sole cause of ultrafiltration failure in CAPD patients. Nevertheless it may be an important component of this pathological process. For example, it has recently been suggested that peritonitis (itself a major cause of ultrafiltration failure) may interact with glycation in the development of peritoneal structural lesions: demesothelialization during peritonitis may expose the underlying stroma to extremely high glucose concentrations [12, 54] . Future studies need to establish the degree of glycation and AGE product formation occurring on the peritoneal membrane itself during treatment with CAPD. Dialysate dwell time, hours 
